Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors

By LabMedica International staff writers
Posted on 09 May 2025

Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. More...

Introducing a flexible, decentralized sequencing system at the point of care, which requires minimal technical oversight, could significantly improve turnaround times and expand patient access to genomic profiling. In a new study, researchers assessed the clinical feasibility of an automated, decentralized cfDNA next-generation sequencing (NGS) assay designed to identify actionable genetic alterations in advanced solid tumors.

The study, conducted by researchers at the Japanese Foundation for Cancer Research (JFCR, Tokyo, Japan), involved genomic profiling of plasma cfDNA from 298 patients with advanced solid tumors using an automated NGS assay. The team compared the tumor mutations detected in plasma cfDNA with those found in patient-matched tumor tissues, which were analyzed using an FDA-approved assay. They also examined clinical factors that could influence the sensitivity of ctDNA aberration (mut-ctDNA) detection. The researchers discovered that the sequencing success rates for cfDNA genomic profiling were significantly higher compared to archived tumor tissue (99% vs. 96%). The detection rates of mut-ctDNA ranged from 20% to 67% across various solid tumors, and targetable or resistance alterations were identified in 18% of patients.

The results, published in the journal Clinical Chemistry, also revealed that approximately 72% of patients showed consistent alterations between tissue and plasma samples. This level of concordance was linked to factors such as cancer type, tumor burden, and the metastatic location. Importantly, 63 plasma-only alterations were identified in 18% of patients, with these alterations being more common in patients who had previously received targeted treatments (24%) compared to those who had undergone chemotherapy (10%). The findings highlight the clinical viability of an automated, decentralized cfDNA genomic profiling method and emphasize the need to consider clinical factors when choosing between plasma- or tissue-based assays. This approach holds promise for improving patient access to timely genomic profiling and facilitating targeted therapy selection.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
POC Immunoassay Analyzer
Procise DX
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.